
US-based private wealth manager Bernstein has taken stock of three large Danish drugmakers – Novo Nordisk, Lundbeck and Genmab – resulting in share price target changes for all three, Bloomberg News reports.
Bernstein has increased Novo Nordisk’s target to DKK 800 from DKK 750 (USD 117 from 109), labeling the stock ”outperform.”
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app